Ann-Lii Cheng, MD, PhD, on Hepatocellular Carcinoma: Trial Results on Lenvatinib vs Sorafenib

2017 ASCO Annual Meeting
Tweet this page

Ann-Lii Cheng, MD, PhD, of the National Taiwan University Hospital, discusses phase III study findings on lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. (Abstract 4001)

Advertisement

Advertisement



Advertisement